The Japan Pruritus Therapeutics Market, valued at US$ 582.2 million in 2023, is set to experience robust growth over the forecast period. With an expected market size of US$ 1,011.5 million by 2032, ...

The use of oral edaravone for a total of 144 weeks is safe and well-tolerated among patients with amyotrophic lateral ...

Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key ...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced 11 presentations will be shared at the American Academy of Neurology (AAN) 2025 Annual Meeting, taking place April 5-9 in San Diego, CA, and ...

In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...

Japan’s leading chemical producers are in the midst of a restructuring intended to shift their focus from traditional ...

The firm acts on some of Japan’s most prominent transactions, including Bain Capital's $3.3 billion pharma acquisition of ...

A 5-deal listicle that explores trends driving attraction to the packaging and storage segment; a look at an add-on deal by a ...

March 26, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma ...

"These findings help build upon our understanding of edaravone's potential effects in ALS," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "By modulating TDP-43 ...

TOKYO -- About 90% of patients with "obesity disease" in Japan perceive the medical condition as a personal responsibility, ...